Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI
Por um escritor misterioso
Descrição
Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.
Darolutamide and Survival in Metastatic, Hormone-Sensitive
Nubeqa Delays Prostate Cancer Progression in Resistant Prostate
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival
New Prostate Cancer Treatment Approved in The U.S.
FDA approves Bayer's Nubeqa® (darolutamide), a new treatment for
Testosterone suppression plus enzalutamide versus testosterone
Androgen receptor pathway inhibitors, prostate cancer, and older
Cancers, Free Full-Text
Prostate cancer Nature Reviews Disease Primers
de
por adulto (o preço varia de acordo com o tamanho do grupo)
